December 18 brings a milestone for cell therapy in graft-versus-host disease—and a setback for Duchenne muscular dystrophy research, …
December 18 brings a milestone for cell therapy in graft-versus-host disease—and a setback for Duchenne muscular dystrophy research, …
With generative AI powering personalized insights, Dexcom’s new Stelo CGM enters the market as the first FDA-cleared over-the-counter …
Blending single-cell biology with generative AI, Cellarity launches its first-in-human trial for CLTY-101—an engineered cell therapy targeting tumor …
Moderna’s mRNA-1345 demonstrates 83% efficacy against RSV in adults 60+, positioning it as a frontrunner in next-gen respiratory …
Roche’s PD-L1 inhibitor demonstrates durable response in RET-mutant thyroid cancer, offering a new option for patients with limited …
Pfizer’s ambitious gene therapy for Duchenne muscular dystrophy fails to meet efficacy targets, prompting strategic retreat and industry-wide …
Despite high hopes, Roche’s anti-amyloid antibody shows no significant benefit in slowing cognitive decline, prompting reevaluation of Alzheimer’s …
The biotech firm discontinues its ReFocus-ALZ and ReThink-ALZ trials, marking a major shift in its neurodegenerative disease strategy.
New molecular imaging techniques show promise in improving cancer surgery precision and outcomes.
Arvinas and Pfizer’s vepdegestrant becomes the first oral PROTAC therapy approved for ER-positive breast cancer, opening new avenues …
Already a subscriber? Log in